Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Nangalia, Jyoti  [Clear All Filters]
2024
Zhao J, Cato LD, Arora UP, Bao EL, Bryant SC, Williams N, Jia Y, Goldman SR, Nangalia J, Erb MA, et al. Inherited blood cancer predisposition through altered transcription elongation. Cell. 2024.
Guo J, Walter K, Quiros PM, Gu M, E Baxter J, Danesh J, Di Angelantonio E, Roberts D, Guglielmelli P, Harrison CN, et al. Inherited polygenic effects on common hematological traits influence clonal selection on JAK2 and the development of myeloproliferative neoplasms. Nat Genet. 2024.
2023
Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL, et al. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023:JCO2201935.
2021
Chapman MSpencer, Nangalia J. Caught in the antiviral crossfire: Ganciclovir-associated mutagenesis in HSC transplant recipients. Cell Stem Cell. 2021;28(10):1683-1685.
Alvarez-Larran A, Sant'Antonio E, Harrison C, Kiladjian J-J, Griesshammer M, Mesa R, Ianotto JChristophe, Palandri F, Hernández-Boluda JCarlos, Birgegård G, et al. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol. 2021;8(9):e658-e665.
2019
Nangalia J, Campbell PJ. Genome Sequencing during a Patient's Journey through Cancer. N Engl J Med. 2019;381(22):2145-2156.
2018
Godfrey AL, Campbell PJ, Maclean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol. 2018:JCO2018788414.
2015
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, E Baxter J, Massie CE, Papaemmanuil E, Menon S, et al. Effect of Mutation Order on Myeloproliferative Neoplasms. N Engl J Med. 2015;372(7):601-612.
Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691.
2014
Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2014;2014(1):287-296.
Li J, Kent DG, Godfrey AL, Manning H, Nangalia J, Aziz A, Chen E, Saeb-Parsy K, Fink J, Sneade R, et al. JAK2V617F-homozygosity drives a phenotypic switch between myeloproliferative neoplasms in a murine model, but is insufficient to sustain clonal expansion. Blood. 2014.